FIELD: medicine.
SUBSTANCE: group of inventions refers to malignant neoplasm treatment. Combination for separate administration comprises a pharmaceutical composition containing a monoclonal anti-CEACAM1 human antibody or antigen-binding fragment thereof; and a pharmaceutical composition comprising a monoclonal antibody against one of human PD-1, human PD-L1 and human PD-L2, or an antigen-binding fragment thereof; wherein said monoclonal antibody is capable of inhibiting or blocking the interaction of PD-1 with at least one of its ligands. Also disclosed is a method of treating a patient suffering cancer and a kit of reagents with instructions for use.
EFFECT: group of inventions provides a synergic increase in lymphocyte cytotoxicity.
49 cl, 9 dwg, 2 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| NOVEL ANTI-PD-1 ANTIBODIES | 2016 |
|
RU2729830C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2776121C2 |
| NEW ANTI-PD-L1 ANTIBODIES | 2017 |
|
RU2744959C2 |
| HUMAN MONOCLONAL ANTIBODIES TO THE PROTEIN OF PROGRAMMED DEATH 1 (PD-1) AND METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTIC AGENTS | 2016 |
|
RU2732924C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
